With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.578743-87-0,[1,3-Bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper chloride,as a common compound, the synthetic route is as follows.,578743-87-0
Chloro[l,3-bis(2,6-di-i-propylphenyl)imidazol-2-ylidene]copper(I) (195.1 mg, 0.4 mmol) and silver triflate (102.7 mg, 0.4 mmol) were mixed under nitrogen in 25 mL flask and 10 mL of dry THF were added. Reaction mixture was stirred at RT for 30 minutes.Solution of 2,2′-bipyridine (62.4 mg, 0.4 mmol) in dry THF (5 mL) was added. Reaction mixture turned orange and was stirred at RT overnight. Resulting mixture was filtered through Celite and solvent was evaporated on rotovap. Recrystallization from CH2CI2 by vapor diffusion of EtaO gave 215 mg (70.9%) of orange crystals. Anal, calcd. forC38H44CUF3N4O3S: C, 60.26; H, 5.86; N, 7.40; Found: C, 60.18; H, 5.82; N, 7.38. Structure was confirmed by iH-NMR spectrum of [(IPR)Cu(bipy)]OTf (CDCb, 400MHz).
As the paragraph descriping shows that 578743-87-0 is playing an increasingly important role.
Reference£º
Patent; THE UNIVERSITY OF SOUTHERN CALIFORNIA; THOMPSON, Mark; DJUROVICH, Peter; KRYLOVA, Valentina; WO2011/63083; (2011); A1;,
Copper catalysis in organic synthesis – NCBI
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”